Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lundbeck Convinces NICE To Back Brintellix In MDD

This article was originally published in Scrip

Executive Summary

NICE has decided to recommend H. Lundbeck AS' Brintellix (vortioxetine) for funding on the National Health Service in England and Wales after requesting and receiving more information from the Danish company on the novel antidepressant.



Related Companies